Efavirenz, (R)-

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598164

CAS#: 154801-74-8

Description: Efavirenz, (R)- is a nonnucleoside HIV-1 reverse transcriptase inhibitor. Efavirenz, (R)- is an antiviral.

Chemical Structure

img
Efavirenz, (R)-
CAS# 154801-74-8
Instruction

Theoretical Analysis

MedKoo Cat#: 598164
Name: Efavirenz, (R)-
CAS#: 154801-74-8
Chemical Formula: C14H9ClF3NO2
Exact Mass: 315.03
Molecular Weight: 315.670
Elemental Analysis: C, 53.27; H, 2.87; Cl, 11.23; F, 18.05; N, 4.44; O, 10.14

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Efavirenz, (R)-; L 743725; L-743725; L743725;

IUPAC/Chemical Name: (R)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one

InChi Key: XPOQHMRABVBWPR-CYBMUJFWSA-N

InChi Code: InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m1/s1

SMILES Code: O=C1NC2=CC=C(Cl)C=C2[C@@](C(F)(F)F)(C#CC3CC3)O1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 315.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gleason RL Jr, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One. 2015 Apr 27;10(4):e0117125. doi: 10.1371/journal.pone.0117125. eCollection 2015. PubMed PMID: 25915208; PubMed Central PMCID: PMC4411122.

2: Arpadi SM, Shiau S, Strehlau R, Patel F, Mbete N, McMahon DJ, Kaufman JJ, Coovadia A, Kuhn L, Yin MT. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016 Oct 23;30(16):2459-2467. PubMed PMID: 27427876; PubMed Central PMCID: PMC5069169.

3: Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736. Epub 2014 Jan 23. PubMed PMID: 24458091.

4: Vesterbacka J, Nowak P, Barqasho B, Abdurahman S, Nyström J, Nilsson S, Funaoka H, Kanda T, Andersson LM, Gisslèn M, Sönnerborg A. Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One. 2013;8(1):e55038. doi: 10.1371/journal.pone.0055038. Epub 2013 Jan 28. PubMed PMID: 23383047; PubMed Central PMCID: PMC3557242.

5: Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero M, del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Med. 2016 May;17(5):340-9. doi: 10.1111/hiv.12314. Epub 2015 Sep 10. PubMed PMID: 27089862.

6: Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333. PubMed PMID: 25202920; PubMed Central PMCID: PMC4404408.

7: Young J, Schäfer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC; Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012 Mar 13;26(5):567-75. doi: 10.1097/QAD.0b013e32834f337c. PubMed PMID: 22398568.

8: Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, Wajima T, Savina P, Peppercorn A, Castellino S, Wagner D, Hosking L, Mosteller M, Rubio JP, Piscitelli SC. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8. Epub 2014 Aug 23. PubMed PMID: 25146692; PubMed Central PMCID: PMC4158172.

9: Tiraboschi J, Hamzah L, Teague A, Kulasegaram R, Post F, Jendruleck I, Murray T, Fox J. Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study. AIDS Res Hum Retroviruses. 2016 Dec;32(12):1198-1201. Epub 2016 Aug 22. PubMed PMID: 27216134.

10: Metzger IF, Quigg TC, Epstein N, Aregbe AO, Thong N, Callaghan JT, Flockhart DA, Nguyen AT, Stevens CK, Gupta SK, Desta Z. Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers. Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9. doi: 10.1016/j.curtheres.2014.05.002. eCollection 2014 Dec. PubMed PMID: 25352936; PubMed Central PMCID: PMC4209507.

11: Kwara A, Cao L, Yang H, Poethke P, Kurpewski J, Tashima KT, Mahjoub BD, Court MH, Peloquin CA. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy. 2014 Mar;34(3):265-71. doi: 10.1002/phar.1388. Epub 2014 Jan 13. PubMed PMID: 24420746; PubMed Central PMCID: PMC3947488.

12: Torres B, Rallón NI, Loncá M, Díaz A, Alós L, Martínez E, Cruceta A, Arnaiz JA, Leal L, Lucero C, León A, Sánchez M, Negredo E, Clotet B, Gatell JM, Benito JM, Garcia F. Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial. AIDS Res Hum Retroviruses. 2014 May;30(5):425-33. doi: 10.1089/AID.2013.0185. Epub 2014 Feb 10. PubMed PMID: 24380397; PubMed Central PMCID: PMC4010173.

13: Gleason RL Jr, Caulk AW, Seifu D, Rosebush JC, Shapiro AM, Schwartz MH, Eckard AR, Amogne W, Abebe W. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia. J Biomech. 2016 Sep 6;49(13):2584-2592. doi: 10.1016/j.jbiomech.2016.05.018. Epub 2016 May 21. PubMed PMID: 27270208.

14: Yin K, Meng X, Dong P, Ding T, Shen L, Zhang L, Zhang R, Cai W, Lu H. A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector. Biosci Trends. 2014 Aug;8(4):227-34. PubMed PMID: 25224629.

15: Taniguchi T, Grubb JR, Nurutdinova D, Önen NF, Shacham E, Donovan M, Overton ET. Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care. J Int Assoc Provid AIDS Care. 2013 Mar-Apr;12(2):138-41. doi: 10.1177/1545109712467057. Epub 2012 Dec 26. PubMed PMID: 23269514.

16: Honório Tda S, Pinto EC, Rocha HV, Esteves VS, dos Santos TC, Castro HC, Rodrigues CR, de Sousa VP, Cabral LM. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. AAPS PharmSciTech. 2013 Sep;14(3):1244-54. doi: 10.1208/s12249-013-0016-4. Epub 2013 Aug 14. PubMed PMID: 23943401; PubMed Central PMCID: PMC3755163.

17: Jiang F, Desta Z, Shon JH, Yeo CW, Kim HS, Liu KH, Bae SK, Lee SS, Flockhart DA, Shin JG. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013 Jan;75(1):244-53. doi: 10.1111/j.1365-2125.2012.04314.x. Erratum in: Br J Clin Pharmacol. 2013 Apr;75(4):1171. PubMed PMID: 22554354; PubMed Central PMCID: PMC3555064.

18: Wang Q, Young J, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Fehr J, Bucher HC, Battegay M; Swiss HIV Cohort Study. Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. HIV Clin Trials. 2014 May-Jun;15(3):92-103. doi: 10.1310/hct1503-92. PubMed PMID: 24947533.

19: Meyer zu Schwabedissen HE, Oswald S, Bresser C, Nassif A, Modess C, Desta Z, Ogburn ET, Marinova M, Lütjohann D, Spielhagen C, Nauck M, Kroemer HK, Siegmund W. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. Clin Pharmacol Ther. 2012 Jul;92(1):103-11. doi: 10.1038/clpt.2012.34. Epub 2012 May 16. Erratum in: Clin Pharmacol Ther. 2013 Jan;93(1):129. Dosage error in article text. PubMed PMID: 22588604; PubMed Central PMCID: PMC3667667.

20: Calderón MM, Penzak SR, Pau AK, Kumar P, McManus M, Alfaro RM, Kovacs JA. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. Clin Infect Dis. 2016 Apr 15;62(8):1036-1042. doi: 10.1093/cid/ciw028. Epub 2016 Jan 20. PubMed PMID: 26797214; PubMed Central PMCID: PMC4803107.